1,053 results on '"Avet Loiseau, Herve"'
Search Results
2. NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma
3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
4. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
5. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group
6. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation
7. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
8. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
9. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
10. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
11. MRD in multiple myeloma: does CR really matter?
12. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
13. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
14. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
15. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
16. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
17. Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
18. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
19. In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
20. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
21. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
22. IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM
23. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
24. Risk factors in multiple myeloma: is it time for a revision?
25. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
26. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
27. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
28. Development of hyperdiploidy starts at an early age and takes a decade to complete
29. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
30. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
31. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
32. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma
33. Cytogénétique et génétique moléculaire du myélome multiple
34. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
35. Prognosis of Myeloma/Genetics of Myeloma
36. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
37. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
38. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow
39. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
40. Biologie du myélome multiple : utilité clinique
41. Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
42. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
43. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
44. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
45. RAS/RAF landscape in monoclonal plasma cell conditions
46. P-369 Single cell multi-omic correlation of single nucleotide variants, copy number variation and surface epitopes for clonal profiling of myeloma
47. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study
48. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
49. Prognostic role of circulating exosomal miRNAs in multiple myeloma
50. Timing the initiation of multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.